Israel - Ibrani - Ministry of Health

פישר מעבדות פרמצבטיות בעמ - שמן ג'ל לגוף

Israel - Ibrani - Ministry of Health

novartis israel ltd - ondansetron as hydrochloride dihydrate - תמיסה להזרקה - ondansetron as hydrochloride dihydrate 2 mg/ml - ondansetron - ondansetron - adults:zofran is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. zofran is indicated for the prevention and treatment of post-operative nausea and vomiting (ponv). paediatric population:zofran is indicated for the management of chemotherapy-induced nausea and vomiting (cinv) in children aged ?6 months, and for the prevention and treatment of ponv in children aged ?2 years.

Israel - Ibrani - Ministry of Health

inovamed ltd - ondansetron as hydrochloride dihydrate 2 mg / 1 ml - solution for injection - ondansetron - adults:ondansetron inovamed is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. ondansetron inovamed is indicated for the prevention and treatment of post-operative nausea and vomiting (ponv). paediatric population:ondansetron inovamed is indicated for the management of chemotherapy-induced nausea and vomiting (cinv) in children aged ?6 months, and for the prevention and treatment of ponv in children aged ?2 years.

Israel - Ibrani - Ministry of Health

neopharm (israel) 1996 ltd - ondansetron as hydrochloride dihydrate - תמיסה להזרקה - ondansetron as hydrochloride dihydrate 2 mg/ml - ondansetron - ondansetron - adults:for the mangement of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy.for the prevention and treatment of post-operative nausea and vomiting (ponv).paediatric population:for the mangement of chemotherapy-induced nausea and vomiting (cinv) in children aged ? 6 months, and for the prevention and treatment of ponv in children aged ? 2 years.

Israel - Ibrani - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - ondansetron as hydrochloride dihydrate - תמיסה להזרקה - ondansetron as hydrochloride dihydrate 2 mg/ml - ondansetron - ondansetron - adults: odnatron is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. odnatron is indicated for the prevention and treatment of post-operative nausea and vomiting (ponv).paediatric population: odantron is indicated for the management of chemotherapy-induced nausea and vomiting (cinv) in children aged ?6 months, and for the prevention and treatment of ponv in children aged ?2 years.

Israel - Ibrani - Ministry of Health

tzamal bio-pharma ltd - metformin hydrochloride; pioglitazone as hydrochloride - טבליות מצופות פילם - metformin hydrochloride 850 mg; pioglitazone as hydrochloride 15 mg - metformin - metformin - competact is indicated as second line treatment of type 2 diabetes mellitus adult patients,particularly overweight patients, who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.after initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in hba1c). in patients who fail to show an adequate response, pioglitazone should be discontinued. in light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.

Israel - Ibrani - Ministry of Health

sanofi israel ltd - clopidogrel as hydrogen sulfate - טבליות מצופות פילם - clopidogrel as hydrogen sulfate 75 mg - clopidogrel - clopidogrel - prevention of atherotrobmotic eventsclopidogrel is indicated in :• adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.• adult patients suffering from acute coronary syndrome- non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave myocardial infarction (mi)), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapyprevention of atherotrobmotic and thromboembolic events in atrial fibrillation: in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for the treatment with vitamin k antagonists (vka) anti-thrombin or anti factor xa, and who have a low bleeding risk, clopid

Israel - Ibrani - Ministry of Health

teva israel ltd - clopidogrel as bisulfate - טבליה - clopidogrel as bisulfate 75 mg - clopidogrel - clopidogrel - clopidogrel is indicated for the prevention of atherothrombotic events as follows : * recent mi recent stroke or established peripheral arterial disease : - patients suffering from myocardial infarction (from a few days until less than 35 days ) - ischaemic stroke ( from 7 days until less than 6 months) or established peripheral arterial disease. - for patients with a history of recent myocardial infarction (mi) recent stroke or established peripheral arterial disease - clopidogrel has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not) new mi (fatal or not) and other vascular death. * acute coronary syndrome: - for patients with acute coronary syndrome [non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave mi) or st segment elevation acute myocardial infarction ] in combination with asa in medically treated patients eligible for thrombolytic therapy and those who are to be managed with percutaneous coronary intervention (with or without stent) or

Israel - Ibrani - Ministry of Health

teva pharmaceutical industries ltd, israel - clopidogrel as bisulfate - טבליה - clopidogrel as bisulfate 75 mg - clopidogrel - clopidogrel - clopidogrel is indicated for the prevention of atherothrombotic events as follows : * recent mi recent stroke or established peripheral arterial disease : - patients suffering from myocardial infarction (from a few days until less than 35 days ) - ischaemic stroke ( from 7 days until less than 6 months) or established peripheral arterial disease. - for patients with a history of recent myocardial infarction (mi) recent stroke or established peripheral arterial disease - clopidogrel has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not) new mi (fatal or not) and other vascular death. * acute coronary syndrome: - for patients with acute coronary syndrome [non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave mi) or st segment elevation acute myocardial infarction ] in combination with asa in medically treated patients eligible for thrombolytic therapy and those who are to be managed with percutaneous coronary intervention (with or without stent) or

Israel - Ibrani - Ministry of Health

sanofi - aventis israel ltd - clopidogrel as hydrogen sulfate 300 mg - film coated tablets - clopidogrel - prevention of atherotrobmotic eventsclopidogrel is indicated in :• adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.• adult patients suffering from acute coronary syndrome- non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave myocardial infarction (mi)), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapyprevention of atherotrobmotic and thromboembolic events in atrial fibrillation: in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for the treatment with vitamin k antagonists (vka) anti-thrombin or anti factor xa, and who have a low bleeding risk, clopid